“Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients” (2024) Biomolecules and Biomedicine, 24(6), pp. 1586–1594. doi:10.17305/bb.2024.10528.